Oncoplastic reduction mammoplasty for breast cancer in women with macromastia: Oncological long-term outcomes.

[OBJECTIVE] To evaluate the long-term results of tumorectomy and concomitant bilateral oncoplastic reduction mammoplasty (ORM) for early stage breast cancer patients with macromastia in terms of local disease control and long-term oncological results.

[PATIENTS AND METHOD] Data of 82 patients with macromastia undergoing ORM for breast cancer between 1996 and 2011 were retrospectively examined and evaluated with regard to oncological results.

[RESULTS] The median age was 50 years. The median follow-up was 121 months (range 28-212 months). The median breast volume was 1402 cm and the median weight of excised breast material was 679 g. The median surgical margin was 16 mm. Ten-year local recurrence rate was 8.7%. The 10-year overall survival rate was 82.2% and the disease-free survival rate was 73.2%. Early and late complication rates were 12.2% and 14.6%, respectively.

[CONCLUSIONS] From the standpoint of local disease control and long-term observation, ORM can be considered a very safe and acceptable treatment for early stage breast cancer in women with macromastia.